Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers
Background: Cladribine tablets 3.5 mg/kg cumulative over 2 years (CT3.5) had significant clinical/imaging effects in patients with clinically isolated syndrome (CIS; ORACLE-MS) or relapsing-remitting MS (RRMS; CLARITY and CLARITY Extension). This analysis compared the effect of cladribine tablets on...
Enregistré dans:
| Auteurs principaux: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
SAGE Publishing
2019-06-01
|
| Collection: | Therapeutic Advances in Neurological Disorders |
| Accès en ligne: | https://doi.org/10.1177/1756286419854986 |
| Tags: |
Pas de tags, Soyez le premier à ajouter un tag!
|